Latest News
& Insights
Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries
Strategic partnership combines Chemspace's ultra-large chemical datasets and Enamine's REAL design principles with Orogen's AI-enabled DEL technology to advance next-generation drug discovery.
Orogen Therapeutics and Chemspace/Enamine Announce a Strategic Collaboration to Enable Unique REAL-Driven DNA Encoded Small Molecule Libraries
Strategic partnership combines Chemspace's ultra-large chemical datasets and Enamine's REAL design principles with Orogen's AI-enabled DEL technology to advance next-generation drug discovery.
Orogen Therapeutics Announces Expansion of Scientific Advisory Board with Drug Discovery and Development Experts
Industry leaders Humphrey Gardner and Christopher Winter, PhD join Orogen's expanded SAB as the Company advances its AI-enabled DNA-encoded library platform.
Orogen Therapeutics Announces Launch of Scientific Advisory Board with AI Drug Discovery Experts
AI-Drug Discovery leaders Rafael Gómez Bombarelli and Ian Watson join Orogen's SAB as the company advances its AI-enabled DNA-encoded library platform.
Orogen Therapeutics Announces Expansion of Board with Biopharma Leaders Mikael Dolsten and Dieter Weinand as Independent Non-Executive Directors
Orogen announces the expansion of its Board of Directors with Independent Non-Executive biopharma leaders Mikael Dolsten, M.D., Ph.D., prior Chief Scientific Officer at Pfizer, and Dieter Weinand, M.S., former CEO of Bayer Pharmaceuticals AG.
Orogen Therapeutics Announces Expansion of Leadership Team with Appointment of CEO and Senior Medicinal Chemist
Orogen Therapeutics announces Mark Pykett, PhD, VMD, MBA, as Chief Executive Officer and Dominque Potin, PhD, as Senior Principal Scientist in medicinal chemistry.
Breakthrough in DNA-Encoded Library Technology Accelerates Drug Discovery Timeline
Orogen's FocusDEL™ platform demonstrates significant efficiency gains in identifying novel chemical matter for challenging therapeutic targets.
"Orogen is elevating new heights in drug discovery, integrating massive chemical libraries, target-specific screening, and AI-based computation to propel the generation of novel medicines."
Mark Pykett
CEO, Orogen Therapeutics